舍曲林联合小剂量阿立哌唑治疗难治性强迫症的对照研究

Control study of aripiprazole added on sretraline in treating refractory obsessive compulsive disorder

目的:探讨舍曲林联合小剂量阿立哌唑治疗难治性强迫症的临床疗效和安全性。方法:选取60例符合CCMD-3中强迫症诊断的患者,随机分为实验组和对照组,实验组30例,应用舍曲林联合小剂量阿立哌唑治疗;对照组30例,单用舍曲林治疗。于治疗前及治疗2周、4周、6周、8周末采用强迫量表评定(Yale-Brown)临床疗效,副反应量表(Tess)评定不良反应。结果:实验组疗效优于对照组(P<0.05),且实验组起效更早,两组2、4、6、8周末Tess评分比较无显著差异(P>0.05)。结论:舍曲林联合小剂量阿立哌唑治疗难治性强迫症比单用舍曲林治疗效果更好,安全性好,是一种值得临床借鉴的策略。

Objective： To evaluate the efficacy and safety of aripiprazole added on sretraline on patients with refractory ob- sessive compulsive disorder. Methods ： All 60 refractory obsessive compulsive disorder patients were randomly divided into sretraline group （ n = 30 ,sretraline 100 - 200 mg/d） , and aripiprazole added on sretraline group （ n =30,sretraline 100 - 200 mg/d, aripiprazole l0 -20 mg/d） and received medication treatment for 8 weeks. The efficacy was assessed with Yale-Brown obsessive-compulsive psychiatrists rating scale （Y-Brown） at the beginning and the 2nd,4th,6th,8th week- end of treatment. The side effects were assessed with the treatment emergent symptom scale （TESS）. Results：There were no difference of scores of TESS among the two groups before and at the 2nd,4th,6th,gth weekend of treatment（ P 〉 O. 05 ）. The Y-Brown score of aripiprazole added on sretraline group was lower than that of sretraline group （P 〈 0.05 ）. Conclusion：Aripiprazole added on sretraline is effective and safe on patients with refractory obsessive compulsive disorder.